219 related articles for article (PubMed ID: 15339056)
1. Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
Natale RB
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):27-31. PubMed ID: 15339056
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
4. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
6. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in non-small cell lung cancer.
Crinò L; Cappuzzo F
Expert Opin Pharmacother; 2002 Jun; 3(6):745-53. PubMed ID: 12036414
[TBL] [Abstract][Full Text] [Related]
8. [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Hosomi Y; Shibuya M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):527-32. PubMed ID: 17431336
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Le Chevalier T; Scagliotti G; Natale R; Danson S; Rosell R; Stahel R; Thomas P; Rudd RM; Vansteenkiste J; Thatcher N; Manegold C; Pujol JL; van Zandwijk N; Gridelli C; van Meerbeeck JP; Crino L; Brown A; Fitzgerald P; Aristides M; Schiller JH
Lung Cancer; 2005 Jan; 47(1):69-80. PubMed ID: 15603856
[TBL] [Abstract][Full Text] [Related]
10. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Bunn PA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
13. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin/gemcitabine combination in advanced NSCLC.
Ramalingam S; Belani CP
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):21-6. PubMed ID: 15339055
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Gandara DR; Lau DH; Lara PN; Edelman MJ
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):26-30. PubMed ID: 10960942
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
[TBL] [Abstract][Full Text] [Related]
17. Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Harper P
Semin Oncol; 2003 Aug; 30(4 Suppl 10):2-12. PubMed ID: 12917815
[TBL] [Abstract][Full Text] [Related]
18. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
[TBL] [Abstract][Full Text] [Related]
20. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Belani CP
Lung Cancer; 2005 Dec; 50 Suppl 2():S3-8. PubMed ID: 16557668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
